BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed LXEO catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:72d7e56910a4c5806237@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:LXEO P1/P2 readout (est.): Gene Therapy for ACM Due to a PKP2 Patho
 genic Variant
DESCRIPTION:Gene Therapy for ACM Due to a PKP2 Pathogenic Variant\nNCT06109
 181 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Lexeo Therapeutics\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nTicker LXEO (confiden
 ce 0.9)\nSource: https://clinicaltrials.gov/study/NCT06109181\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06109181
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
